Technology rose while the S&P 500 fell 0.58%, so yesterday punished broad index ownership more than the AI trade.
That’s the useful part of the session. If you own a broad fund and also own a few big growth names, the index decline may have overstated the damage to your favorite stocks and understated the weakness under the surface. The VIX jumped 8.19%, which says people paid up for protection, but the selling came from the parts of the market that were supposed to broaden the rally. When anxiety rises while technology holds up, your portfolio risk is coming from the names that were meant to diversify the growth exposure.
The drag came from supposed ballast
Health care was the clearest problem, falling 2.52%, while financials also weighed on the index. Energy rose 1.11%, helped by stronger crude, and technology finished higher. That combination tells you the market did not reject earnings growth or AI spending across the board. It marked down businesses with fresh doubts and hid in areas with a cleaner near-term story.
The company news inside health care made the sector move more than a generic defensive-stock wobble. Amgen sank after Novartis’s late-stage pelacarsen failure raised doubts about whether lowering Lp(a) will translate into fewer cardiovascular events, which spilled into concerns about Amgen’s related olpasiran program. Stryker was hit after executives discussed supply-chain problems in peripheral vascular and joint-replacement operations. Those are specific business issues, and they matter because they can pressure earnings expectations even when the economy is not the main concern.
For your portfolio, that means the “safe” label deserves another look. Health care can act defensive when the market is scared of economic weakness, but trial read-throughs and operating problems can overwhelm that role quickly. Financials slipping at the same time made the index feel heavier, because the weakness was not confined to speculative pockets. Broad funds were pulled lower by groups many people own precisely to avoid being too dependent on mega-cap technology.
Catalysts still got paid
The outlier list makes the same point from the other direction. Roivant jumped 18.75% after its mosliciguat study in pulmonary hypertension associated with interstitial lung disease hit its key goal, including a 56.3% reduction in pulmonary vascular resistance versus placebo. NuScale also surged, though no verified news catalyst surfaced. GoPro went the other way after the final $20 million closing under its convertible debenture agreement, a financing structure that can raise dilution concerns.
This is why yesterday was not a plain “sell everything” day. DigitalOcean and CoreWeave also rallied with the AI-cloud trade, while GoPro was punished for balance-sheet financing and Amgen for a pipeline read-through. The market was willing to pay for a cleaner growth story and punish a capital-structure problem in the same session. If you are adding to winners here, you need to know whether you are buying a company-specific catalyst or just a stock that moved because it sits near the hot theme.
The distinction matters because narrow leadership can keep an index looking fine until the laggards become too large to ignore. Technology holding up helped cushion the Nasdaq, but it did not rescue the S&P from health care and financial weakness. The longer that pattern lasts, the more your result depends on the exact mix of sectors inside your account, even if the headline index move looks small.
The open is asking the same question
This morning is not giving you a clean reset. S&P 500 futures are up 0.05% and Nasdaq futures are up 0.15%, while Russell 2000 futures are down 0.05%. The premarket movers keep leaning into the same concentrated-growth corner: Rocket Lab, MicroStrategy, Intuitive Machines, AST SpaceMobile and Qualcomm are higher, while DigitalOcean is giving back a little after its big move.
That setup says the market is still comfortable rewarding selected growth while staying careful on the broader list. If small caps are soft again and the Nasdaq is the only major index with traction, you are looking at a market where stock selection matters more than the index color on your screen. A flat open would not erase yesterday’s message; it would extend the test.
Watch whether health care and financials stop leaking while Nasdaq-linked names keep their gains. If those groups keep sagging, your broad index fund can lose ground even while the AI names on your watchlist look perfectly healthy.